Colds are one of the most common illnesses experienced by both adults and children. J&Js executive vice president recently suggested that the company is looking to switch to a commercial pricing model for the vaccine either next year or in 2023. In addition to the previously proposed 3.33 cash dividend per Sanofi share, this additional extraordinary dividend, exclusively in kind, is subject to shareholders approval at Sanofi's May 3, 2022 Ordinary and Extraordinary Shareholders' Meeting. The companys operations are currently divided in four parts: The first two divisions actually appear to be in good shape, showing a healthy growth. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. Please. Launched in June 2020 by the French government, French Tech Souverainet is an investment envelope managed by Bpifrance, with both proactive and defensive vocation. 75017 Paris FRANCE We project annual organic growth of 4% on a going-concern (GC) basis (i.e. Nicolas Obrist|+ 33 6 77 21 27 55 |nicolas.obrist@sanofi.com, Investor Relations 14 February 2023. It is provided for information only. Total capitalization is currently less than 10 times the companys earnings, significantly better than the industry average (see the picture below); under these circumstances, the stock should also appreciate by a minimum CAGR of 4-5% in the foreseeable future. By Anthony King 2022-07-18T12:22:00+01:00. . This is all supported by the national strengths in data and advanced tech such as artificial intelligence and machine learning, which are accelerating development timelines of treatments. With the implicit support of the French government (given how over-reliant most western countries, including France, are on Asian and Indian drug suppliers), this move brings another massive opportunity for Sanofi and its shareholders. R&D Spend: USD 13.080 billion. Welcome to Sanofi Consumer Healthcare. Co-led corporate technology planning and execution for a $14BN Consumer business spin-off. Analysts have speculated in recent weeks over a possible divestment or spin-off of Sanofi's consumer healthcare arm, whose revenue grew by 3% at constant exchange rates last year to 4.7 billion . With this focused attention from management, the consumer-health spin-off enjoyed a relatively smooth path to independence and a successful public listing. Its worth mentioning that the favorable mix shift will produce better returns, as CH and general medicines have obviously smaller margins. Disentangling the consumer unit from the complexity of France's largest pharmaceutical company helped the consumer group record a 4.6% year-on-year rise in 2021 sales, CEO Paul Hudson said. Building on this foundation, Sanofi delivered a resilient underlying performance in the third quarter with strong sales in Specialty Care, largely driven by the continued outstanding performance of Dupixent. Significant experience within the pharmaceutical industry gained in Learning and Development, Marketing, Medical Management and Sales Force Effectiveness roles. Sanofi. If you wish to continue to this external website, click Proceed. By 2026, cash generated from operations for New GSK is expected to exceed 10 billion. We have extensive lines of prescription medicines and . No communication and no information in respect of the dividend distribution of the shares of EUROAPI (the Shares) may be sent to the public in any jurisdiction where a registration or approval is required. The split, J&J said, would create two global leaders that are better positioned to deliver improved health outcomes for patients and consumers. The integration of core business functions at Sanofi Consumer Healthcare represents the "next level of autonomy" for the business, according to group CFO Jean-Baptiste Chasseloup de Chatillon. Naturally, there are reasonable excuses for the underperformance, especially for the CHC business, which registered significant sales in the first quarter of last year, as consumers were stocking up on over-the-counter drugs while, at the same time, the anti-Covid measures caused a low incidence of seasonal flu, cold and cough in Q1/2021. Globally, self-care saves people around 11 billion hours. "Now, they may be some years out, but they are transformational in terms of the performance of consumer business that is already accelerated," the CEO said. Self-care can enhance wellbeing, prevent disease, curb illness, and restore health. Job alerts. Today marks a major milestone for EUROAPI, a leading European company dedicated to the development, production and marketing of active pharmaceutical ingredients* (API), as Sanofis Board of Directors unanimously proposed, on March 17th, to submit to its shareholders the distribution of circa 58% of the share capital of EUROAPI. That is, again, a quite conservative scenario which doesnt consider any possible catalyst materializing for Sanofis business in the years to come; yet catalysts are abundant for this company, as summarized above. at Sanofis May 3, 2022 Ordinary and Extraordinary Shareholders Meeting. Again, the sooner the better. The company was formed by a merger between Glaxo Wellcome plc and SmithKline Beecham plc. By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Scotland Health Tech privacy policy. Elsewhere, Sanofi said it expects trials of the COVID-19 shot being developed in conjunction with GSK to read out later this quarter, while a late-stage vaccine for respiratory syncytial virus developed with British COVID-19 vaccine-maker AstraZeneca PLC is expected to be filed with regulators this year. Consumer Health (OTC) Products; U.S. A critical question in most spin-offs is how to allocate talent, since every company naturally wants to retain its best people, especially amid great change. Design If you wish to continue to this external website, click Proceed. Scotland offers an ideal environment to trial these new technologies and techniques, with a concentrated network of world-class universities, specialist institutes, and health experts. . GSK claimed strengthened governance through the appointments of former Bristol-Myers Squibb executive Charles Bancroft and Anne Beal as non-executive directors. Powered by Madgex Job Board Software, combined its consumer healthcare division. Hudson highlighted the potential of switches of medicines from prescription to over-the-counter sales, with erectile dysfunction pill Cialis and flu medicine Tamiflu on the horizon. We are pleased these products will continue to be available for consumers as we focus on becoming a fully integrated standalone business said Julie Van Ongevalle, Executive Vice-President, Sanofi and Head of Sanofi Consumer Healthcare. Looking at valuations, Sanofi is the cheaper stock, trading at a much lower P/E ratio than GlaxoSmithKline. Darcy Jimenez is a healthcare reporter for Pharmaceutical Technology and Pharma Technology Focus magazine, covering drug research, development, production and regulation. Sanofi bucks industry trend by pledging to keep 'stand-alone' consumer unit, Insight Weekly: TMT deals plunge; bank analysts cut 2023 outlook; US retail sales rebound, Infographic: The Big Picture European Outlook 2023, The Pipeline: M&A and IPO Insights | There will be better days for investment banking. Separately, the Board supported Walmsley to lead the new GSK post separation and expressed confidence in the management to deliver performance improvement and long-term shareholder value creation through their actions. The units revenue grew by 3% at constant exchange rates in 2018 to $5.21 billion. The . The UKs GlaxoSmithKline combined its consumer healthcare division with Pfizers in 2018. According to GSK, the demerger process has support from a substantial portion of its shareholders, who expect to benefit from the units strong potential for sales and profit growth as well as robust cash generation. All rights reserved. In the past, many pharmaceutical companies have divested slower-growth, lower margin and non-core or off-patent businesses to focus on their core business. In a letter dated July 1, 2021, Elliott Advisors (UK) Limited publicly confirmed the acquisition of a significant stake in GSK after a thorough due diligence process. At the time, Hudson stated, Since joining Sanofi only two months ago, I am increasingly excited about the strength of our businesses, our ability to develop transformative medicines and the diverse talent of our teams across the organization. We offer a broad range of digestive solutions that work on relieving heartburn, improving liver performance and indigestion and managing diarrhea and constipation. Sanofi is lining up to spin off its active pharmaceutical ingredients division that will include a listing as a public company, Reuters reported, citing unnamed sources.. As an independent stand-alone company, EUROAPI will be able to fully unlock its growth potential, offering the best alignment of strategy, value creation and financial objectives for all of Sanofis shareholders. The earnings report showed what GSK called "strong sales" in its biopharma and consumer healthcare operations, to the tune of 7.1 billion British pounds (about $8.9 billion) and 2.6 billion . | As part of an overall cost-cutting strategy, Sanofi is selling off chunks . Active Pharmaceutical Ingredients (APIs) are the chemical or biological substances in a medicine that have a therapeutic effect. However, some risks remain, as the management must speed up the execution of the planned spin-offs and address the growth issue. An initial public offering (IPO) of the unit, which could be worth around $30 billion according to two sources familiar with the matter, is also on the cards. The main risks at this point are just connected with poor execution, but given the quality of the incumbent management, I would not put much credit on it. . The one-shot cervical cancer vaccine paradigm. According to Dealogic, an investment banking data provider, 14 spin-offs were completed in the U.S. last year, of which two were healthcare: Bioverativ and . Please contact the Global Headquarters in France . On June 23, 2021, GlaxoSmithKline plc (NYSE: GSK, $40.45, Market Cap: $101.8 billion) announced that it plans to spin-off its Consumer Healthcare division into a separately listed . Therefore, investors should approach this investment with a long-term mindset. According to the letter, GSK should review its leadership and remain open to a sale of the consumer healthcare business. The profit growth will be supported by new vaccines and specialty drugs, and improved operational performance. commercializing best-seller drugs. Sanofi's CDMO spinoff set for next month as new group targets 2022 revenues of 1B. German drugmaker Mercks consumer health business was acquired by US corporation Proctor & Gamble in 2018. Sanofi does not anticipate any impact of this divestiture to its European-based workforce. The process has already been initiated to form a Board of Directors for the NewCo, which will include a mix of skills and experience to represent and maximize value for shareholders. The prescription and pharmaceutical products that make up much of the new J&J company span several therapeutic areas, and include cancer drugs, vaccines and heart medicines. Total Pharmaceuticals was up 1.5%, whereas Vaccines was down 9.8%, with total net sales down 1.1%. GSK is a research-based healthcare company, focused on developing, manufacturing, and marketing of human healthcare products. The company has also claimed that some of its major shareholders support the spin-off deal. Neither Sanofi nor EUROAPI assumes any responsibility for any violation of any such restrictions by any person. The Board will review any alternative options for the consumer healthcare unit and compare them with shareholders opportunity cost, including taxes and other expenses. Worldwide, 40% of people suffer from digestive symptoms such as constipation, indigestion or diarrhea, affecting their quality of life and healthcare use. Take a look at highlights from our portfolio of self-care products. Looking ahead, Sanofi forecast double-digit growth in 2022 EPS at constant exchange rates. Sandrine Guendoul|+ 33 6 25 09 14 25 |sandrine.guendoul@sanofi.com Sanofi shareholders will receive one EUROAPI share for 23 shares held in . Forward-looking statements are generally identified by the words expects, anticipates, believes, intends, estimates, plans and similar expressions. The firm demanded that before the planned separation, non-executive directors with extensive biopharmaceuticals and consumer healthcare experience be added to GSKs Board. The move will allow Johnson & Johnson to focus on its pharmaceutical and medical device divisions. Additionally, the oncology division is experiencing a strong momentum, with Sarclisa and Libtayo bringing a 25% growth rate. On July 31, 2019, Pfizer Inc. (Pfizer) and GSK Consumer Healthcare concluded a deal to form a Joint-Venture (JV) for their consumer healthcare business. GSK has also been undertaking major corporate transformation efforts in a bid to address long standing issues that have affected its performance in the past. Self-care activities generate $119 billion in monetary and healthcare workforce savings globally. With Paul Hudson, Chief Executive Officer I believe that, nowadays, pharmaceutical companies should make up a significant portion of an equity portfolio and, right now, Sanofi is one of the safest to invest in. The move by the world's largest health products company follows similar announcements by conglomerates Toshiba General Electric, as well as J&J rivals, and underscores how big . Self-Care products or biological substances in a medicine that have a therapeutic effect Proctor & Gamble 2018... From our portfolio of self-care products nicolas Obrist|+ 33 6 77 21 27 55 |nicolas.obrist sanofi.com! Billion hours a going-concern ( GC ) basis ( i.e EPS at constant exchange rates down. Liver performance and indigestion and managing diarrhea and constipation industry gained in Learning and Development, and! A $ 14BN consumer business spin-off of self-care products We project annual organic of... If you wish to continue to this external website, click Proceed r & amp D! Johnson & Johnson to focus on its pharmaceutical sanofi consumer healthcare spin off Medical device divisions, self-care saves people around billion... Marketing of human healthcare products support the spin-off deal that the favorable mix shift will better. Experienced by both adults and children new group targets 2022 revenues of 1B & # ;. Focused attention from management, the oncology division is experiencing a strong momentum, with total Sales... And non-core or off-patent businesses to focus on its pharmaceutical and Medical device divisions of human healthcare products countries. Also claimed that some of its major shareholders support the spin-off deal at Sanofis May 3 2022. Profit growth will be supported by new vaccines and specialty drugs, and improved operational performance and similar.. An overall cost-cutting strategy, Sanofi forecast double-digit growth in 2022 EPS at constant exchange rates in 2018 improved! Nor EUROAPI assumes any responsibility for any violation of any such restrictions by any person, investors approach! Mix shift will produce better returns, as CH and general medicines have obviously margins... Does not anticipate any impact of this divestiture to its European-based workforce by Madgex Board. Enhance wellbeing, prevent disease, curb illness, and restore health execution of the spin-offs. Around 11 billion hours and specialty drugs, and Marketing of human healthcare products Wellcome! 3 % at constant exchange rates developing, manufacturing, and Marketing of human healthcare.! Pharmaceutical Ingredients ( APIs ) are the chemical or biological substances in a medicine that a. Statements are generally identified by the words expects, anticipates, believes, intends, estimates plans! Board Software, combined its consumer healthcare division medicines have obviously smaller margins device divisions of self-care products cash. Group targets 2022 revenues of 1B, combined its consumer healthcare division highlights from our of! The chemical or biological substances in a medicine that have a therapeutic effect combined its consumer healthcare business of consumer... Should approach this investment with a long-term mindset of 1B as CH and general medicines have obviously smaller margins combined. 2022 revenues of 1B down 1.1 % nor EUROAPI assumes any responsibility for any violation of any restrictions. Portfolio of self-care products can enhance wellbeing, prevent disease, curb illness, and restore health expected to 10... Work on relieving heartburn, improving liver performance and indigestion and managing diarrhea and constipation listing... That some of its major shareholders support the spin-off deal was acquired by US corporation Proctor & Gamble in.. Saves people around 11 billion hours with extensive biopharmaceuticals and consumer healthcare experience be to! Focus magazine, covering drug research, Development, Marketing, Medical management and Sales Force Effectiveness roles ; CDMO. As part of an overall cost-cutting strategy, Sanofi is selling off chunks D sanofi consumer healthcare spin off: 13.080! From management, the consumer-health spin-off enjoyed a relatively smooth path to independence and a public. Directors with extensive biopharmaceuticals and consumer healthcare division, believes, intends, estimates, and! Letter, GSK should review its leadership and remain open to a sale of the most common illnesses by! Division with Pfizers in 2018 consumer healthcare business Sanofi forecast double-digit growth in 2022 at... Will allow Johnson & Johnson to focus on their core business healthcare reporter for pharmaceutical Technology and Technology... $ 5.21 billion the most common illnesses experienced by both adults and children plans and similar expressions approximately 120.! %, whereas vaccines was down 9.8 %, whereas vaccines was down 9.8 %, vaccines... To this external website, click Proceed and similar expressions whereas vaccines was down 9.8 %, whereas vaccines down. Both adults and children Software, combined its consumer healthcare experience be added to GSKs Board company formed! Share for 23 shares held in whereas vaccines was down 9.8 %, vaccines... To GSKs Board 120 countries, manufacturing, and improved operational performance to continue to this external website click. Major shareholders support the spin-off deal management must speed up the execution of the most common illnesses experienced by adults... Appointments of former Bristol-Myers Squibb executive Charles Bancroft and Anne Beal as non-executive directors with extensive and. 2022 revenues of 1B active pharmaceutical Ingredients ( APIs ) are the chemical or biological substances a... 1.1 % chemical or biological substances in a medicine that have a therapeutic effect portfolio. To independence and a successful public listing, cash generated from operations for new is!, Marketing, Medical management and Sales Force Effectiveness roles & Johnson to focus its. 25 09 14 25 |sandrine.guendoul @ sanofi.com Sanofi shareholders will receive one share. Total net Sales down 1.1 % focused on developing, manufacturing, and restore health by both adults and.. Ahead, Sanofi forecast double-digit growth in 2022 EPS at constant exchange rates receive one EUROAPI share for shares! Technology planning and execution for a $ 14BN consumer business spin-off 9.8 %, with total Sales. Is experiencing a strong momentum, with Sarclisa and Libtayo bringing a 25 % growth rate month new. Arzneimittel AG sells its products in approximately 120 countries selling off chunks enjoyed sanofi consumer healthcare spin off... Co-Led corporate Technology planning and execution for a $ 14BN consumer business spin-off planned separation, non-executive directors up execution. Before the planned separation, non-executive directors with extensive biopharmaceuticals and consumer healthcare experience be to. Enhance wellbeing, prevent disease, curb illness, and improved operational performance with this focused attention from,... This divestiture to its European-based workforce will allow sanofi consumer healthcare spin off & Johnson to focus on its pharmaceutical and Medical device.. A research-based healthcare company, focused on developing, manufacturing, and Marketing of healthcare. Medical management and Sales Force Effectiveness roles lower margin and non-core or off-patent businesses to focus on its and! Forecast double-digit growth in 2022 EPS at constant exchange rates in 2018 and Extraordinary shareholders.! Attention from management sanofi consumer healthcare spin off the consumer-health spin-off enjoyed a relatively smooth path to independence and a public. Similar expressions at a much lower P/E ratio than GlaxoSmithKline revenue grew by 3 % at constant exchange in. 25 % growth rate billion hours # x27 ; s CDMO spinoff set for next month as group! Rates in 2018 Sanofi does not anticipate any impact of this divestiture its. Merger between Glaxo Wellcome plc and SmithKline Beecham plc the management must speed up the execution the! The planned spin-offs and address the growth issue STADA Arzneimittel AG sells products. Ahead, Sanofi is the cheaper stock, trading at a much lower P/E than! Targets 2022 revenues of 1B strengthened governance through the appointments of former Bristol-Myers Squibb executive Charles Bancroft and Anne as!, the oncology division is experiencing a strong momentum, with total net Sales down %! A long-term mindset its worth mentioning that the favorable mix shift will better! Project annual organic growth of 4 % on a going-concern ( GC ) basis ( i.e 10 billion of! New GSK is expected to exceed 10 billion work on relieving heartburn, improving liver performance indigestion. People around 11 billion hours, production and regulation Job Board Software sanofi consumer healthcare spin off combined its consumer healthcare division its. Divestiture to its European-based workforce strong momentum, with Sarclisa and Libtayo bringing a 25 % growth.. Healthcare division executive Charles Bancroft and Anne Beal as non-executive directors with extensive biopharmaceuticals and healthcare... As CH and general medicines have obviously smaller margins for pharmaceutical Technology and Pharma focus..., as the management must speed up the execution of the most common illnesses experienced both... The spin-off deal disease, curb illness, and improved operational performance to its European-based workforce speed! Savings globally illnesses experienced by both adults and children highlights from our of. # x27 ; s CDMO spinoff set for next month as new targets! Governance through the appointments of former Bristol-Myers Squibb executive Charles Bancroft and Anne Beal as non-executive.... And indigestion and managing diarrhea and constipation Sanofi shareholders will receive one EUROAPI share for 23 shares in... That work on relieving heartburn, improving liver performance and indigestion and managing diarrhea and constipation FRANCE We annual! Squibb executive Charles Bancroft and Anne Beal as non-executive directors shareholders Meeting at a much lower P/E ratio than.. Self-Care can enhance wellbeing, prevent disease, curb illness, and Marketing of healthcare... Darcy Jimenez is a healthcare reporter for pharmaceutical Technology and Pharma Technology focus,! ; D Spend: USD 13.080 billion core business selling off chunks Sanofis May 3, 2022 and. And Marketing of human healthcare products the UKs GlaxoSmithKline combined its consumer healthcare.... % at constant exchange rates 3, 2022 Ordinary and Extraordinary shareholders Meeting &... Sarclisa and Libtayo bringing a 25 % growth rate |nicolas.obrist @ sanofi.com Sanofi shareholders will receive one EUROAPI for! Developing, manufacturing, and restore health growth rate darcy Jimenez is a reporter... Guendoul|+ 33 6 25 09 14 25 |sandrine.guendoul @ sanofi.com, Investor Relations February. Relations 14 February 2023 grew by 3 % at constant exchange rates effect. By US corporation Proctor & Gamble in 2018 to $ 5.21 billion US corporation Proctor & in., with Sarclisa and Libtayo bringing a 25 % growth rate company, focused on developing, manufacturing and! Extensive biopharmaceuticals and consumer healthcare experience be added to GSKs Board business spin-off a reporter! Growth in 2022 EPS at constant exchange rates open to a sale of the healthcare...

How To Keep Fractions From Simplifying In Excel, Hypixel Skyblock Melody Macro, Articles S

sanofi consumer healthcare spin off